Ladies and gentlemen,
|MILAN ANALYTICA AG
fon +41 (0)61 845 99 88
fax +41 (0)61 845 99 87
|MILAN ANALYTICA AG • 4310 Rheinfelden • Switzerland • phone 0041 61 845 99 88|
AbSorber hosted an Early Morning Symposium during the TTS Congress in Vancouver, August 16
Improving outcomes in kidney transplantation: Non-HLA antibodies and Enhanced Clinical Risk Assessment
HLA-specific antibodies present before kidney transplantation or induced after transplantation have been associated with hyperacute and acute vascular rejection episodes, graft loss, and poor long-term graft survival. There is increasing evidence that the presence of non-HLA antibodies reactive with donor endothelial cells contribute to short and long term complications in renal transplant recipients. During the symposium enhanced risk assessment focusing on the detection of non-HLA antibodies was discussed.
AbSorber is excited about the very positive interest that XM-ONE has received in the transplant community around the world. AbSorber's symposium, at this important congress, gave the participants an even better understanding of the clinical role of XM-ONE in organ transplantation, according to Anders Karlsson, CEO of AbSorber.
XM-ONE is a standardized, cell based, crossmatch test for clinical use. The use of XM-ONE allows you to identify patients at risk for developing acute rejections and post-transplant complications. XM-ONE provides additional information compared to the currently used lymphocyte crossmatch tests and therefore improves the basis for risk assessment prior to transplantation.
|If you do not want to receive such information, please send an e-mail to firstname.lastname@example.org.|